Dr. June Almenoff is an accomplished biopharma executive with 20 years of senior leadership experience in the pharmaceutical industry. She served as President and Chief Marketing Officer of Furiex Pharmaceuticals, which was acquired by Actavis plc (now Allergan) for $1.2B. Furiex developed eluxadoline (Viberzi®), which was recently approved in both the United States and Europe. Prior to joining Furiex, Dr. Almenoff was at GlaxoSmithKline (GSK) for 12 years, where she held various positions of increasing responsibility. She was a Vice President in the Clinical Safety Organization, chaired a PhRMA-FDA working group, and worked in the area of scientific licensing. Dr. Almenoff also led the development of pioneering systems for minimizing risk in drug development, which have been widely adopted by industry and regulators.

Dr. Almenoff is currently an independent biopharma consultant and Board Director. She has strong expertise in translational medicine, clinical development, commercial strategy, and business development.  She is the Chief Scientific Officer of RedHill Biopharma Ltd. (Nasdaq: RDHL) and is also on the investment advisory board of the Harrington Discovery Institute. She has served as an advisor or Board Director to numerous venture-backed and public biotech companies.
Dr. Almenoff received her B.A. cum laude from Smith College and graduated with AOA honors from the M.D.-Ph.D. program at the Icahn (Mt. Sinai) School of Medicine. She completed post-graduate medical training at Stanford University Medical Center and served on the faculty of Duke University School of Medicine.  She is an adjunct professor at Duke, a Fellow of the American College of Physicians (FACP) and has authored more than 50 publications.